Lilly’s 2021 Double-Digit Growth Comes From COVID-19 Drugs, New Products

Prevail Purchase For $880m Adds Gene Therapy Capabilities

 
• By Mandy Jackson
Business man showing pie chart in color background
Lilly forecasts growth across its portfolio of newer commercial products

More from Business

More from Scrip